Literature DB >> 6333679

The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors.

K Schilling, S Liao.   

Abstract

Tritiated 7 alpha, 17 alpha-dimethyl-19-nortestosterone (DMNT; mibolerone), a synthetic androgen stable to metabolic conversion in the rat ventral prostate, is an excellent radioactive ligand for the quantitation and characterization of androgen receptors in prostate, liver, and cultured cells. DMNT is more receptor-selective than 17 alpha-methyl-17 beta-hydroxy-estra-4,9,11-trien-3-one (R1881); DMNT interacts with glucocorticoid and progestin receptors much less strongly than R1881. Unlike 5 alpha-dihydrotestosterone, DMNT does not bind tightly to testosterone-estradiol binding globulin of human serum. The hydroxylapatite-filter assay we employed can clearly distinguish between DMNT binding to androgen receptors of rat ventral prostate and interaction of DMNT with androgen binding protein of epididymides. The prostate cytosol (3H)DMNT-receptor complex sediments in two forms (4 and 8 S) in a low salt medium. In 0.4 M KCl, both the prostate cytosol and nuclear (3H)DMNT-receptor complexes migrated as 3-4 S components. The formation of both the cytosol and nuclear DMNT-receptor complexes is inhibited by antiandrogens and 17 beta-estradiol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333679     DOI: 10.1002/pros.2990050603

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Authors:  Jacob Kach; Tiha M Long; Phillip Selman; Eva Y Tonsing-Carter; Maria A Bacalao; Ricardo R Lastra; Larischa de Wet; Shane Comiskey; Marc Gillard; Calvin VanOpstall; Diana C West; Wen-Ching Chan; Donald Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz
Journal:  Mol Cancer Ther       Date:  2017-04-20       Impact factor: 6.261

2.  Autoimmune anti-androgen-receptor antibodies in human serum.

Authors:  S Liao; D Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate.

Authors:  L Castagnetta; G Carruba; E Fecarotta; M Lo Casto; R Cusimano; M Pavone-Macaluso
Journal:  Urol Res       Date:  1992

4.  A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).

Authors:  S N Freeman; W I Mainwaring; B J Furr
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

5.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.

Authors:  Anu-Maarit Moilanen; Reetta Riikonen; Riikka Oksala; Laura Ravanti; Eija Aho; Gerd Wohlfahrt; Pirjo S Nykänen; Olli P Törmäkangas; Jorma J Palvimo; Pekka J Kallio
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.